A new era in tackling brain diseases

Nanocarry is developing a new class of brain therapeutics, which combines biological approaches with nanoparticles to allow biologics to cross the Blood Brain Barrier, creating first-in-class therapeutics for neuro-oncology indications and CNS diseases.

Nanocarry’s Team & Story

Powered by the convergence of multidisciplinary expertise
Nanocarry is developing an innovative delivery technology platform pioneered over the past decade in the Nano-Bioengineering lab of Prof. Rachela Popovtzer at Bar Ilan University, Israel. With pre-seed financing from NfX and TechBio, Nanocarry’s nano-chemistry and biology labs are working synergistically to develop first-in-class product candidates, while scaling and optimizing the manufacturing process of its bioengineered gold nanoparticles.

Meet Nanocarry’s Multidisciplinary Team

Revital Mandil Levin

CEO & Co-founder

Oshra Betzer

COO & Co-founder

Rachela Popovtzer

CSO & Co-founder

Adam Antebi

Director of CMC

Ayelet Zafran

Head of Biology

Michal Roytman

CBO

Ashley Shapiro

Communications & BD Associate

Roni Neria

Research Assistant

Ariel Sella

Board Member, UnBox Ventures

Aaron Zucker

Board Member, Sapir Venture Partners

Omri Amirav-Drory

Board Member, NFX

Meet Nanocarry’s Advisory Team

Shani Paluch-Shimon, MD

Director of Breast Oncology, Hadassah Medical Center

Iris Alroy

Co-Founder and CSO, Anima Biotech, Expert in Preclinical Development

Ofra Levy Hacham

VP RA/Clinical, Solgel Technologies, Expert in CMC and Regulation
Linkedin
© 2022 Nanocarry Therapeutics, all rights reserved.

designed by Studio7Design

Skip to content